Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.56
ABBV's Cash to Debt is ranked higher than
60% of the 1152 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.37 vs. ABBV: 0.56 )
ABBV' s 10-Year Cash to Debt Range
Min: 0.51   Max: No Debt
Current: 0.56

Equity to Asset 0.06
ABBV's Equity to Asset is ranked lower than
56% of the 1034 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.58 vs. ABBV: 0.06 )
ABBV' s 10-Year Equity to Asset Range
Min: -0.01   Max: 0.74
Current: 0.06

-0.01
0.74
Interest Coverage 7.95
ABBV's Interest Coverage is ranked higher than
53% of the 618 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 176.76 vs. ABBV: 7.95 )
ABBV' s 10-Year Interest Coverage Range
Min: 7.95   Max: 9999.99
Current: 7.95

7.95
9999.99
Z-Score: 3.74
WACC vs ROIC
12.96%
26.19%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 17.09
ABBV's Operating margin (%) is ranked higher than
87% of the 1102 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.84 vs. ABBV: 17.09 )
ABBV' s 10-Year Operating margin (%) Range
Min: 17.09   Max: 31.65
Current: 17.09

17.09
31.65
Net-margin (%) 8.89
ABBV's Net-margin (%) is ranked higher than
78% of the 1102 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.10 vs. ABBV: 8.89 )
ABBV' s 10-Year Net-margin (%) Range
Min: 8.89   Max: 28.7
Current: 8.89

8.89
28.7
ROE (%) 42.66
ABBV's ROE (%) is ranked higher than
98% of the 1129 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.93 vs. ABBV: 42.66 )
ABBV' s 10-Year ROE (%) Range
Min: 24.85   Max: 199.32
Current: 42.66

24.85
199.32
ROA (%) 6.21
ABBV's ROA (%) is ranked higher than
79% of the 1161 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.32 vs. ABBV: 6.21 )
ABBV' s 10-Year ROA (%) Range
Min: 6.25   Max: 22.67
Current: 6.21

6.25
22.67
ROC (Joel Greenblatt) (%) 80.26
ABBV's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 1156 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.14 vs. ABBV: 80.26 )
ABBV' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 96.79   Max: 244.26
Current: 80.26

96.79
244.26
» ABBV's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

ABBV Guru Trades in Q2 2014

Lee Ainslie 3,235,133 sh (New)
Louis Moore Bacon 185,000 sh (New)
Jana Partners 75,000 sh (New)
NWQ Managers 83,878 sh (New)
Paul Tudor Jones 257,344 sh (New)
Ken Fisher 1,104,609 sh (+76.13%)
Manning & Napier Advisors, Inc 192,029 sh (+31.46%)
Tom Russo 86,777 sh (unchged)
Robert Bruce 231,300 sh (unchged)
Westport Asset Management 180,000 sh (unchged)
Jeremy Grantham Sold Out
Dodge & Cox 36,649 sh (-0.14%)
PRIMECAP Management 6,304,122 sh (-0.50%)
Mario Gabelli 10,382 sh (-0.76%)
John Hussman 300,000 sh (-1.07%)
Pioneer Investments 2,014,581 sh (-1.52%)
Murray Stahl 35,273 sh (-1.70%)
Bill Frels 264,316 sh (-2.08%)
Jeff Auxier 73,421 sh (-6.40%)
Jim Simons 2,233,600 sh (-20.14%)
George Soros 150,000 sh (-57.14%)
Joel Greenblatt 88,923 sh (-61.19%)
» More
Q3 2014

ABBV Guru Trades in Q3 2014

Steven Cohen 184,300 sh (New)
Andreas Halvorsen 10,769,105 sh (New)
John Paulson 13,000,000 sh (New)
Steve Mandel 5,247,201 sh (New)
George Soros 1,537,146 sh (+924.76%)
Lee Ainslie 4,723,578 sh (+46.01%)
Jana Partners 100,000 sh (+33.33%)
Dodge & Cox 38,849 sh (+6.00%)
NWQ Managers 85,948 sh (+2.47%)
PRIMECAP Management 6,454,836 sh (+2.39%)
Paul Tudor Jones 261,700 sh (+1.69%)
Pioneer Investments 2,601,836 sh (unchged)
Tom Russo 86,777 sh (unchged)
Robert Bruce 231,300 sh (unchged)
Westport Asset Management 180,000 sh (unchged)
Mario Gabelli 10,382 sh (unchged)
Murray Stahl 35,265 sh (-0.02%)
Bill Frels 263,837 sh (-0.18%)
Manning & Napier Advisors, Inc 186,088 sh (-3.09%)
Ken Fisher 999,768 sh (-9.49%)
Louis Moore Bacon 80,000 sh (-56.76%)
Jeff Auxier 27,371 sh (-62.72%)
John Hussman 100,000 sh (-66.67%)
Jim Simons 722,355 sh (-67.66%)
Joel Greenblatt 9,460 sh (-89.36%)
» More
Q4 2014

ABBV Guru Trades in Q4 2014

Jean-Marie Eveillard 1,016,097 sh (New)
Mario Gabelli 34,557 sh (+232.85%)
Pioneer Investments 3,102,193 sh (+19.23%)
NWQ Managers 96,015 sh (+11.71%)
PRIMECAP Management 6,578,886 sh (+1.92%)
Bill Frels 267,837 sh (+1.52%)
Manning & Napier Advisors, Inc 187,451 sh (+0.73%)
Robert Bruce 232,915 sh (+0.70%)
Ken Fisher 1,001,105 sh (+0.13%)
Westport Asset Management 180,000 sh (unchged)
John Hussman 100,000 sh (unchged)
John Paulson Sold Out
Lee Ainslie Sold Out
Steve Mandel Sold Out
Steven Cohen Sold Out
George Soros Sold Out
Andreas Halvorsen Sold Out
Jana Partners Sold Out
Tom Russo 86,718 sh (-0.07%)
Murray Stahl 35,158 sh (-0.30%)
Jeff Auxier 27,071 sh (-1.10%)
Dodge & Cox 38,055 sh (-2.04%)
Joel Greenblatt 8,759 sh (-7.41%)
Louis Moore Bacon 30,044 sh (-62.45%)
Jim Simons 217,900 sh (-69.83%)
Paul Tudor Jones 12,914 sh (-95.07%)
» More
Q1 2015

ABBV Guru Trades in Q1 2015

Manning & Napier Advisors, Inc 187,414 sh (-0.02%)
» More
» Details

Insider Trades

Latest Guru Trades with ABBV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on AbbVie Inc

Lountzis Asset Management Comments on Abbvie - Mar 21, 2014

ABBVIE (ABBV), spun off from Abbott, represents their research-based proprietary pharmaceutical business and is led by its highly profitable Humira franchise. Humira makes up approximately 50% of revenues and over 70% of profits. While AbbVie is focused on growing its pipeline, the reality is Humira, the leading rheumatoid arthritis drug, will continue to drive the revenue and profit growth for AbbVie until some of the experimental drugs they are working on such as its Hepatitis C virus drug gains FDA approval and enters the market. As a result, we are reviewing our holding of AbbVie at this time given its enormous concentration on one drug. While it continues to lead in many areas and it continues to grow around the world, it remains a concern for us. AbbVie’s revenues in 2013 exceeded $18.8 billion with operating earnings of $5.7 billion.



From Lountzis Asset Management 2013 Annual Letter



Check out latest stock trades

Top Ranked Articles about AbbVie Inc

John Paulson's Top 5 New Holdings For Q3
John Paulson (Trades, Portfolio)’s hedge fund Paulson & Co. was founded in 1994 and has $22.8 billion in assets under management as of Jul 2014. The fund focuses primarily on event-driven arbitrage situations. Paulson’s top strategies, the Advantage and Advantage Plus funds, lost 4.8 percent and 3.9 percent this year through August, the New York Times reported. Read more...
The 5 Most-Owned Spin-Offs of Investment Gurus
Numerous financiers, including Joel Greenblatt (Trades, Portfolio), have posited that investors can beat the market by investing in spin-offs – small portions of larger companies separated to stand as their own, independent company. But is this true? This is a question that GuruFocus writer Vera Yuan pondered in her article, “Can Spin-Offs Beat the Market?” Her research concluded that 52 weeks after being spun off, all spun-off companies since 2009 collectively outperformed the market by 84.28%. For this reason, GuruFocus introduced the “Spin-Off List” screener, which tracks all companies spun off since 2013. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 60.50
ABBV's P/E(ttm) is ranked higher than
70% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 64.60 vs. ABBV: 60.50 )
ABBV' s 10-Year P/E(ttm) Range
Min: 9.86   Max: 63.84
Current: 60.5

9.86
63.84
Forward P/E 12.84
ABBV's Forward P/E is ranked higher than
94% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. ABBV: 12.84 )
N/A
PE(NRI) 60.60
ABBV's PE(NRI) is ranked higher than
74% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 61.40 vs. ABBV: 60.60 )
ABBV' s 10-Year PE(NRI) Range
Min: 9.85   Max: 63.95
Current: 60.6

9.85
63.95
P/B 60.61
ABBV's P/B is ranked lower than
63% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.13 vs. ABBV: 60.61 )
ABBV' s 10-Year P/B Range
Min: 15.75   Max: 63.95
Current: 60.61

15.75
63.95
P/S 5.33
ABBV's P/S is ranked lower than
51% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.19 vs. ABBV: 5.33 )
ABBV' s 10-Year P/S Range
Min: 2.83   Max: 5.68
Current: 5.33

2.83
5.68
PFCF 36.10
ABBV's PFCF is ranked higher than
84% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. ABBV: 36.10 )
ABBV' s 10-Year PFCF Range
Min: 8.64   Max: 38.09
Current: 36.1

8.64
38.09
POCF 29.90
ABBV's POCF is ranked higher than
80% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 45.91 vs. ABBV: 29.90 )
ABBV' s 10-Year POCF Range
Min: 8.19   Max: 31.54
Current: 29.9

8.19
31.54
EV-to-EBIT 31.64
ABBV's EV-to-EBIT is ranked higher than
78% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 43.18 vs. ABBV: 31.64 )
ABBV' s 10-Year EV-to-EBIT Range
Min: 10.3   Max: 33.7
Current: 31.64

10.3
33.7
Current Ratio 1.41
ABBV's Current Ratio is ranked higher than
58% of the 1100 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.13 vs. ABBV: 1.41 )
ABBV' s 10-Year Current Ratio Range
Min: 1.25   Max: 2.59
Current: 1.41

1.25
2.59
Quick Ratio 1.31
ABBV's Quick Ratio is ranked higher than
65% of the 1100 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. ABBV: 1.31 )
ABBV' s 10-Year Quick Ratio Range
Min: 1.1   Max: 2.43
Current: 1.31

1.1
2.43
Days Inventory 89.63
ABBV's Days Inventory is ranked higher than
83% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 148.81 vs. ABBV: 89.63 )
ABBV' s 10-Year Days Inventory Range
Min: 67.2   Max: 93.77
Current: 89.63

67.2
93.77
Days Sales Outstanding 78.47
ABBV's Days Sales Outstanding is ranked higher than
75% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 89.68 vs. ABBV: 78.47 )
ABBV' s 10-Year Days Sales Outstanding Range
Min: 78.47   Max: 93.3
Current: 78.47

78.47
93.3

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.78
ABBV's Dividend Yield is ranked higher than
87% of the 681 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.30 vs. ABBV: 2.78 )
ABBV' s 10-Year Dividend Yield Range
Min: 0.85   Max: 3.44
Current: 2.78

0.85
3.44
Dividend Payout 1.51
ABBV's Dividend Payout is ranked higher than
69% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. ABBV: 1.51 )
ABBV' s 10-Year Dividend Payout Range
Min: 0.63   Max: 1.51
Current: 1.51

0.63
1.51
Yield on cost (5-Year) 2.90
ABBV's Yield on cost (5-Year) is ranked higher than
76% of the 688 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.53 vs. ABBV: 2.90 )
ABBV' s 10-Year Yield on cost (5-Year) Range
Min: 0.85   Max: 3.44
Current: 2.9

0.85
3.44

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.22
ABBV's Price/Median PS Value is ranked higher than
80% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. ABBV: 1.22 )
ABBV' s 10-Year Price/Median PS Value Range
Min: 0.67   Max: 1.21
Current: 1.22

0.67
1.21
Earnings Yield (Greenblatt) 3.20
ABBV's Earnings Yield (Greenblatt) is ranked higher than
74% of the 1148 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.90 vs. ABBV: 3.20 )
ABBV' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3   Max: 9.7
Current: 3.2

3
9.7

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare: » details
Traded in other countries:ABBV.Switzerland, ABBV.France, 4AB.Germany, 0QCV.UK, ABBV.Mexico,
AbbVie Inc was incorporated in Delaware on April 10, 2012, and is a wholly owned subsidiary of Abbott. The company is a research-based biopharmaceutical company with portfolio of proprietary products including a broad line of adult and pediatric pharmaceuticals. The company discovers, develops, manufactures and sells proprietary pharmaceutical products. Its products are used to treat diseases including rheumatoid arthritis, psoriasis, Crohn's disease, HIV, cystic fibrosis complications. AbbVie also has a pipeline of new medicines, including more than 20 compounds or indications in Phase II or Phase III development across such important medical specialties as immunology, renal care, hepatitis C, women's health, oncology, and neuroscience, including multiple sclerosis and Alzheimer's disease. AbbVie operates in one business segment—pharmaceutical products. AbbVie competes with other research-based pharmaceuticals and biotechnology companies that discover, manufacture, market, and sell proprietary pharmaceutical products and biologics.
» More Articles for NYSE:ABBV

Headlines

Articles On GuruFocus.com
AbbVie Focusing On Diversification Routes To Put Higher Sales Numbers On The Board Apr 24 2015 
Analyzing Chris Davis' Top Holdings Apr 14 2015 
Gilead Experiencing Bumpy Ride Despite Strong Fundamentals Apr 03 2015 
AbbVie Strikes The Biggest Deal For Treatment Of Cancer Mar 10 2015 
Top Stock Picks Among Companies That Recently Increased Dividends Mar 09 2015 
AbbVie To Acquire Biopharmaceutical Firm Pharmacyclics Mar 06 2015 
Cracking The Best Healthcare Dividend Stock Secrets Mar 02 2015 
Dogs Of The S&P 500 - No Dividend Alternatives Are Cheaper! Feb 21 2015 
Achillion Pharmaceuticals Stock Soars Following Successful Mid-Stage Hep C Drug Combo Trial Feb 10 2015 
Gilead Sciences Offering Fresh Wave Of Competition To AbbVie’s Viekira Pak Feb 06 2015 


More From Other Websites
4 Top-Rated Drugmakers Reporting Earnings This Week Apr 26 2015
2:15 am AbbVie: FDA grants priority review to AbbVie for investigational, all-oral, interferon-free... Apr 26 2015
Bristol-Myers says hepatitis C drug combination succeeds in study Apr 25 2015
Enanta Pharmaceuticals Announces Preliminary Data from AbbVie’s Phase 3b RUBY-I Study in Chronic... Apr 25 2015
AbbVie Presents Late-Breaking, Preliminary Phase 3b Data with VIEKIRAX® + EXVIERA® in Chronic... Apr 25 2015
AbbVie Presents Late-Breaking, Preliminary Phase 3b Data with VIEKIRAX® + EXVIERA® in Chronic... Apr 25 2015
Inversion Deals Aren’t Dead, They’re Just More Low-Key: Real M&A Apr 25 2015
Inversion Deals Aren't Dead, They're Just More Low-Key Apr 25 2015
AbbVie's HCV Cocktail Treatment Under FDA Priority Review - Analyst Blog Apr 24 2015
Eli Lilly (LLY) Earnings Analysis: By the Numbers Apr 24 2015
AbbVie Hepatitis C Drug Granted Priority FDA Review Apr 24 2015
AbbVie (ABBV) Earnings Report: Q1 2015 Conference Call Transcript Apr 24 2015
U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for... Apr 24 2015
Merck oral hepatitis C regimen shows 95 pct cure rate Apr 24 2015
U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for... Apr 23 2015
Biogen Earnings Preview: What To Look For Apr 23 2015
AbbVie Profit Rises on Broad Sales Growth Apr 23 2015
Doomsday Plan for AbbVie Means Preserving Profits at All Costs Apr 23 2015
AbbVie Beats Q1 Estimates; Novartis, Alexion Mixed Apr 23 2015
AbbVie Beats Earnings on Humira and HCV Sales, Ups View - Analyst Blog Apr 23 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK